SCHEMBL17907416

SCHEMBL17907416

CCOC(=O)c1c(OCC)ccn(-c2ccccc2)c1=O

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.48
RECQL P46063 1/20 0.48
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 2/20 0.48
PDE4D Q08499 1/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPT P10636 3/20 0.46
GAA P10253 2/20 0.46
GABRA2 P47869 2/20 0.45
GABRB2 P47870 2/20 0.45
POLB P06746 1/20 0.43
PABPC1 P11940 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
TP53 P04637 1/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15506038 0.88 GLA (0.43) TSHRALDH1A1PDE4DKMT2ALMNA
SCHEMBL3665276 0.87 AXL (0.49) ALDH1A1KDM4EPDE4DMEN1KMT2A
SCHEMBL16386606 0.85 KDM4E (0.51) TSHRRECQLALDH1A1KDM4EPDE4D
SCHEMBL22249751 0.82 ALDH1A1 (0.41) TSHRRECQLALDH1A1KDM4EPDE4D
SCHEMBL16366161 0.80 LMNA (0.41) RECQLALDH1A1KDM4EPDE4DMEN1
SCHEMBL24297150 0.80 KDM4E (0.40) TSHRRECQLALDH1A1KDM4EPDE4D
SCHEMBL22235128 0.80 MET (0.42) ALDH1A1KDM4EPDE4DMAPTTP53
SCHEMBL22234429 0.79 MET (0.41) ALDH1A1KDM4EPDE4DTP53
SCHEMBL11627353 0.77 COMT (0.55) TSHRRECQLALDH1A1KDM4EPDE4D
SCHEMBL21383502 0.76 MET (0.43) ALDH1A1KDM4EPDE4DMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230172914-A1 BIOMARKER-BASED THERAPEUTIC COMPOSITION WELLMARKER BIO CO., LTD. (KR) 2023-06-08 US disclosed
EP-3819300-A1 BIOMARKER-BASED THERAPEUTIC COMPOSITION Wellmarker Bio Co., Ltd. (KR) 2021-05-12 EP disclosed
CN-112771053-A Biomarker-based therapeutic compositions 伟迈可生物有限公司 2021-05-07 CN disclosed
WO-2021045279-A1 BIOMARKER-BASED THERAPEUTIC COMPOSITION 웰마커바이오 주식회사 2021-03-11 WO disclosed
EP-3042905-B1 PROTEIN KINASE INHIBITOR CONTAINING PYRROLOPYRIDAZINE DERIVATIVE WELLMARKER BIO CO LTD (KR) 2020-06-17 EP disclosed
US-9815840-B2 Protein kinase inhibitor containing pyrrolopyridazine derivative THE ASAN FOUNDATION (KR) 2017-11-14 US disclosed
US-20160207931-A1 PROTEIN KINASE INHIBITOR CONTAINING PYRROLOPYRIDAZINE DERIVATIVE CJ HEALTHCARE CORPORATION (KR) 2016-07-21 US disclosed
EP-3042905-A1 PROTEIN KINASE INHIBITOR CONTAINING PYRROLOPYRIDAZINE DERIVATIVE CJ Healthcare Corporation (KR) 2016-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230172914-A1 BIOMARKER-BASED THERAPEUTIC COMPOSITION KRAS, RET, NRAS TSHR 1115/4885RECQL 3281/4885ALDH1A1 3257/4885
US-20160207931-A1 PROTEIN KINASE INHIBITOR CONTAINING PYRROLOPYRIDAZINE DERIVATIVE MAPKAPK5, MAP3K5, PRKCA TSHR 3922/4885RECQL 4070/4885ALDH1A1 2605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.